Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Biomaterials. 2021 Aug 20;277:121079. doi: 10.1016/j.biomaterials.2021.121079

Figure 1: PFK15 reduces glycolysis in BMDCs and prevents their activation in vitro.

Figure 1:

(a) Schematic of soluble PFK15 reprograms glycolysis in BMDCs with PFKFB3 inhibition. (b) In the presence of LPS, PFK15 significantly lowered the glycolysis (extracellular acidification rate - ECAR) in BMDCs (n = 30–36, avg ± SEM, * - p<0.05). (c) Flow cytometry demonstrates that PFK15 is capable of decreasing CD86 expression in BMDCs. (d) in the presence of LPS, PFK15 significantly decreased CD86HiMHCII+ BMDC populations as compared to LPS, respectively (n = 5–11, avg ± SEM, * - p<0.05).